Search
for

    Glossary JAK2 inhibitor

    blocks enzyme activity to regulate immune function and cell growth

    A JAK2 inhibitor is a type of medication that blocks the activity of Janus kinase 2 (JAK2), an enzyme involved in the signaling pathways that regulate immune function and cell growth. By inhibiting JAK2, these drugs can help manage conditions like certain cancers, autoimmune diseases, and inflammatory disorders, and they are also being explored for treating alopecia areata, a condition that causes hair loss.

    Related Terms

    Research 10 of 586

    1. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature Journal of Dermatological Treatment · 2016 · 40 citations
    2. Under Development JAK Inhibitors for Dermatologic Diseases Mediterranean Journal of Rheumatology · 2020 · 14 citations
    3. Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology International Journal of Dermatology Venereology and Leprosy Sciences · 2024
    4. Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway Indian Dermatology Online Journal · 2023
    5. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata Clinical, cosmetic and investigational dermatology · 2021 · 40 citations
    6. Jak inhibitors in the treatment of alopecia areata - a literature review Journal of Education Health and Sport · 2025
    7. 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Journal of the American Academy of Dermatology · 2024 · 2 citations
    8. 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial Journal of the American Academy of Dermatology · 2023 · 2 citations
    9. The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy JAAD case reports · 2023
    10. IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA Asian journal of pharmaceutical and clinical research · 2017
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →